Q BioMed Announces 2nd Closing on Funding and Advances Cancer Palliation Drug

COMPANY GEARS UP FOR PRODUCTION OF CANCER PAIN PALLIATION DRUG WITH COMMERCIAL LAUNCH EXPECTED IN Q2 2017   NEW YORK, March 22, 2017 — Q BioMed Inc. (OTCQB: QBIO), has closed on its 2nd tranche of the $4,000,000 funding announced on November 30th 2016. The company received $1,000,000 on the 2nd closing bringing the total […]

Read More

NEW SNN Interview with Q BioMed Inc. CEO Mr. Denis Corin at the Marcum Microcap Conference June 2016

In this video interview, Mr. Corin and SNN host Robert Kraft discuss the following topics: Overview of Q BioMed Inc. Update since our last interview (Click here) Discusses recent news and catalysts New potential FDA approved Drug License Deal What differentiates QBIO from the competition Communicating the stories of projects under development Near-term goals and […]

Read More


New Near Term Revenue Asset Deal Pending and MAN-01 Drug Candidate Optimization and Selection Progressing on Schedule NEW YORK, June 1, 2016 — Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company is pleased to report on new potential asset license/acquisition and an update on Man 01 development. We are pleased to announce that we […]

Read More
Social media & sharing icons powered by UltimatelySocial